Actually the article claims that CBD “could be damaging our livers in the same way as alcohol and other drugs." ... the evidense was taken by a study from researchers at the University of Arkansas in Little Rock.
Of course, they never mention that the drug that the researchers used was the EPIDIOLEX, wich is a prescription medicine that is used to treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.
Also the doses was extremely higher than the normal (20mg/kg)...
Also the doses was extremely higher than the normal (20mg/kg)...
"Animals were gavaged with either 0, 246, 738, or 2460 mg/kg of CBD or with daily doses of 0, 61.5, 184.5, or 615 mg/kg for 10 days. A dose of 246 mg/kg was chosen as an initial dose as this is a MED analogous to those used in recent clinical trials (MED of 20 mg/kg CBD).
Subsequently, researchers used doses of 738 and 2460 mg/kg CBD as 3× and 10× doses, respectively. Finally they demonstrated that CBD, when delivered orally to mice in the form of a concentrated CBD-enriched Cannabis extract, has the potential to cause liver injury...
So, on the basis of such an inaccurate article, we thought about doing our own research on CBD and the potential benefits it may have to the liver-related diseases...
Studies About CBD and Liver...
-In a 2008 study, published on PubMed.org researchers found that the "EC system" is highly up-regulated during chronic liver diseases and, to date, it has been implicated in the progression of fibrosis to cirrhosis and the development of the cardiovascular abnormalities of cirrhosis, such as the hyperdynamic circulatory syndrome and cirrhotic cardiomiopathy.
Furthermore, the EC system has positive influences the mechanisms responsible for cell damage and the inflammatory response during acute liver injury, Thus, molecules targeting the CB(1) and CB(2) receptors may represent potential therapeutic agents for the treatment of liver diseases.
At present, the CB(1) antagonists represent the most attractive pharmaceutical tool to resolve fat accumulation in patients with non-alcoholic fatty liver disease and to treat patients with cirrhosis, as they may slow the progression of fibrosis and attenuate the cardiovascular alterations associated with the advanced stage of the disease.
-In a 2011 study, published in NCBI researchers investigated the effects of cannabidiol on brain and liver functions in a model of hepatic encephalopathy (Hepatic encephalopathy is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure.)
They concluded that the results demonstrates the therapeutic effects of CBD in an acute model of HE. It appears that the effect of CBD is multifactorial and involves cannabinoid, vanilloid and 5-HT1A receptors. CBD can improve the symptoms by affecting both brain histopathology and liver function, and thus may serve as therapeutic agent for treating human HE.
-In another study, wich published in 2017 in NCBI, the researchers investigated the Potential of CBD for the Treatment of Viral Hepatitis
They stated that "We report here, for the first time, studies to demonstrate the antiviral activity of CBD against HCV. A review of the literature seems to suggest that CBD may also have positive activity, based on its interaction with the CB2 receptor and as such using a host mechanism to indirectly slow the pathogenic process of the HBV virus. Based on these findings, CBD as such has potential to be further developed as a treatment for viral hepatitis, especially as a combination therapy with the currently existing therapies."
-And the last study was published in 2018 reserchers explore "The Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease"
They found that emerging evidence suggests that the endocannabinoid system and its associated cannabinoid receptors and ligands have mechanistic and therapeutic implications in metabolic derangements and specifically in NAFLD. Cannabinoid receptor 1 antagonism has demonstrated promising effects with increased resistance to hepatic steatosis, reversal of hepatic steatosis, and improvements in glycemic control, insulin resistance, and dyslipidemia.
Exocannabinoids and endocannabinoids have demonstrated some therapeutic impact on metabolic derangements associated with NAFLD, although literature regarding direct therapeutic use in NAFLD is limited. Nonetheless, the properties of the endocannabinoid system, its receptors, substrates, and ligands remain a significant arena warranting further research, with potential for a pharmacologic intervention for a disease with an anticipated increase in economic and clinical burden.
-Also in https://www.liversupport.com they mention how does CBD Oil support your Liver.
Conclusion...
There is scant evidence to suggest that CBD itself causes any issues with liver function at low levels. While there still need to be more human trials before scientists get a full picture of how CBD truly helps people, so far there is a pretty strong outlook for how taking CBD oil can help support your liver.
However, it’s still important to keep some key things in mind. One of the first things to keep an eye out for is low-quality CBD, which may harm your liver by exposing it to toxins. And if you are already using prescription medications, speak to your physician before proceeding with CBD.
Studies About CBD and Liver...
-In a 2008 study, published on PubMed.org researchers found that the "EC system" is highly up-regulated during chronic liver diseases and, to date, it has been implicated in the progression of fibrosis to cirrhosis and the development of the cardiovascular abnormalities of cirrhosis, such as the hyperdynamic circulatory syndrome and cirrhotic cardiomiopathy.
Furthermore, the EC system has positive influences the mechanisms responsible for cell damage and the inflammatory response during acute liver injury, Thus, molecules targeting the CB(1) and CB(2) receptors may represent potential therapeutic agents for the treatment of liver diseases.
At present, the CB(1) antagonists represent the most attractive pharmaceutical tool to resolve fat accumulation in patients with non-alcoholic fatty liver disease and to treat patients with cirrhosis, as they may slow the progression of fibrosis and attenuate the cardiovascular alterations associated with the advanced stage of the disease.
-In a 2011 study, published in NCBI researchers investigated the effects of cannabidiol on brain and liver functions in a model of hepatic encephalopathy (Hepatic encephalopathy is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure.)
They concluded that the results demonstrates the therapeutic effects of CBD in an acute model of HE. It appears that the effect of CBD is multifactorial and involves cannabinoid, vanilloid and 5-HT1A receptors. CBD can improve the symptoms by affecting both brain histopathology and liver function, and thus may serve as therapeutic agent for treating human HE.
-In another study, wich published in 2017 in NCBI, the researchers investigated the Potential of CBD for the Treatment of Viral Hepatitis
They stated that "We report here, for the first time, studies to demonstrate the antiviral activity of CBD against HCV. A review of the literature seems to suggest that CBD may also have positive activity, based on its interaction with the CB2 receptor and as such using a host mechanism to indirectly slow the pathogenic process of the HBV virus. Based on these findings, CBD as such has potential to be further developed as a treatment for viral hepatitis, especially as a combination therapy with the currently existing therapies."
-And the last study was published in 2018 reserchers explore "The Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease"
They found that emerging evidence suggests that the endocannabinoid system and its associated cannabinoid receptors and ligands have mechanistic and therapeutic implications in metabolic derangements and specifically in NAFLD. Cannabinoid receptor 1 antagonism has demonstrated promising effects with increased resistance to hepatic steatosis, reversal of hepatic steatosis, and improvements in glycemic control, insulin resistance, and dyslipidemia.
Exocannabinoids and endocannabinoids have demonstrated some therapeutic impact on metabolic derangements associated with NAFLD, although literature regarding direct therapeutic use in NAFLD is limited. Nonetheless, the properties of the endocannabinoid system, its receptors, substrates, and ligands remain a significant arena warranting further research, with potential for a pharmacologic intervention for a disease with an anticipated increase in economic and clinical burden.
-Also in https://www.liversupport.com they mention how does CBD Oil support your Liver.
Conclusion...
There is scant evidence to suggest that CBD itself causes any issues with liver function at low levels. While there still need to be more human trials before scientists get a full picture of how CBD truly helps people, so far there is a pretty strong outlook for how taking CBD oil can help support your liver.
However, it’s still important to keep some key things in mind. One of the first things to keep an eye out for is low-quality CBD, which may harm your liver by exposing it to toxins. And if you are already using prescription medications, speak to your physician before proceeding with CBD.
No comments:
Post a Comment